

No. 2011-1313, -1372

UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT

MEDTRONIC, INC.,

Plaintiff-Cross-Appellant,

v.

BOSTON SCIENTIFIC CORPORATION
and GUIDANT CORPORATION,

Defendants,

and

MIROWSKI FAMILY VENTURES, LLC,

Defendant-Appellant.

Appeal from the United States District Court for the District of Delaware
in case no. 07-CV-0823, Judge Sue L. Robinson

**COMBINED PETITION OF MEDTRONIC, INC.
FOR PANEL REHEARING AND REHEARING *EN BANC***

Martin R. Lueck
Jan M. Conlin
Stacie E. Oberts
ROBINS, KAPLAN, MILLER &
CIRESI L.L.P.
2800 LaSalle Plaza
800 LaSalle Avenue
Minneapolis, Minnesota 55402-2015
(612) 349-8500

October 18, 2012

Attorneys for Petitioner Medtronic, Inc.

CERTIFICATE OF INTEREST

Counsel for Plaintiff-Cross-Appellant Medtronic, Inc. certifies the following:

1. The full name of every party or amicus represented in this appeal is:
Medtronic, Inc.
2. The names of the real parties in interest represented in this appeal are:
Medtronic, Inc.
3. The names of all parent corporations and any publicly held companies that own 10 percent of the party represented are:
None
4. The names of all law firms and the partners and associates that are expected to appear in this appeal for Plaintiff-Cross-Appellant Medtronic, Inc.:

ROBINS, KAPLAN, MILLER & CIRESI L.L.P.: Martin R. Lueck, Jan M. Conlin, Stacie E. Oberts

The following law firms and counsel formerly appeared for Plaintiff-Cross-Appellant Medtronic, Inc. in the district court in prior phases of the case:

ROBINS, KAPLAN, MILLER & CIRESI L.L.P.: Martin R. Lueck, Jan M. Conlin, Stacie E. Oberts, Richard M. Martinez, Christopher A. Seidl, Sharon E. Roberg-Perez

CONNOLLY, BOVE, LODGE & HUTZ: Arthur G. Connolly, III

TABLE OF CONTENTS

Page

STATEMENT OF COUNSEL.....	1
INTRODUCTION.....	2
BACKGROUND.....	5
ARGUMENT	6
I. The Panel Opinion Directly Conflicts with Precedents Holding the Patentee Bears the Burden of Proof on Infringement Even Where a Declaratory Judgment Defendant Does Not Assert a Counterclaim.....	6
II. Nothing in <i>MedImmune</i> Alters the Traditional Burden of Proof	7
III. <i>Reliance</i> Does Not Support the Panel’s Decision Because There Is No Presumption of Infringement.....	9
IV. The Panel’s Decision Has Dramatic and Far-Reaching Impact	12
CONCLUSION	15

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>Advance Transformer Co. v. Levinson</i> , 837 F.2d 1081 (Fed. Cir. 1988).....	3, 7
<i>Aero Spacelines, Inc. v. United States</i> , 530 F.2d 324 (Ct. Cl. 1976)	2, 11
<i>Am. Eagle Ins. Co. v. Thompson</i> , 85 F.3d 327 (8th Cir. 1996).....	10
<i>Centricut, LLC v. Esab Group, Inc.</i> , 390 F.3d 1361 (Fed. Cir. 2004).....	6
<i>Fireman’s Fund Ins. Co. v. Videfreeze Corp.</i> , 540 F.2d 1171 (3d Cir. 1976).....	10
<i>L & W, Inc. v. Shertech, Inc.</i> , 471 F.3d 1311 (Fed. Cir. 2006).....	6
<i>Lykes Bros. Steamship Co. v. United States</i> , 459 F.2d 1393 (Ct. Cl. 1972)	2, 10, 11
<i>MedImmune, Inc. v. Genentech, Inc.</i> , 549 U.S. 118 (2007).....	1, 3, 4, 7, 8, 12, 13
<i>Microsoft Corp. v. i4i Ltd. P’ship</i> , 131 S.Ct. 2238 (2011)	10
<i>R.R. Co. v. Mellon</i> , 104 U.S. 112 (1881).....	1, 2, 8, 12
<i>Reliance Life Ins. Co. v. Burgess</i> , 112 F.2d 234 (8th Cir. 1940).....	2, 9, 11
<i>Under Sea Indus, Inc. v. Dacor Corp.</i> , 833 F.2d 1551 (Fed. Cir. 1987).....	3, 6
<i>Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc.</i> , 200 F.3d 795 (Fed. Cir. 1999).....	1, 3, 6, 7

TABLE OF AUTHORITIES
(Continued)

Page(s)

Other Authorities

12 James Wm. Moore et al., <i>Moore's Federal Practice</i> § 57.62[2][d] (3d ed. 1997).....	7
Borchard, <i>Declaratory Judgments</i> 404-05 (2d ed. 1941).....	11
George E. Dix et al., 2 <i>McCormick on Evidence</i> § 344 (Kenneth S. Broun ed., 6th ed. 2006).....	11

STATEMENT OF COUNSEL

Based on my professional judgment, I believe the panel decision is contrary to the following decision(s) of the Supreme Court of the United States and the precedent(s) of this Court: *MedImmune, Inc. v. Genentech, Inc.*, 549 U.S. 118 (2007); *R.R. Co. v. Mellon*, 104 U.S. 112 (1881); *Vivid Techs., Inc. v. Am. Sci. & Eng'g, Inc.*, 200 F.3d 795 (Fed. Cir. 1999).

Based on my professional judgment, I believe this appeal requires an answer to one or more precedent-setting questions of exceptional importance:

Whether a legal presumption of patent infringement should exist such that in a declaratory judgment action brought by a licensee seeking a declaration of non-infringement the burden of proof is shifted to the declaratory judgment plaintiff to prove non-infringement.



Martin R. Lueck, Esq.

ATTORNEY OF RECORD FOR MEDTRONIC, INC.

INTRODUCTION

The panel held, contrary to this Court's precedent, that declaratory judgment plaintiff Medtronic, Inc. bears the burden of proving non-infringement. The panel relied on an Eighth Circuit insurance case from 1940, referring to it as "the leading case which expounded the guiding principles for allocating the burden of proof in a declaratory judgment action." Slip Op. at 11-12 (citing *Reliance Life Ins. Co. v. Burgess*, 112 F.2d 234 (8th Cir. 1940)) (internal quotation omitted).

Reliance does not support the conclusion reached by the panel. *Reliance* stands for the proposition that the burden of proof should always be placed on the party that asserts the affirmative of the issue (*i.e.*, infringement) unless there is an established legal presumption that applies to that central issue. See *Reliance*, 112 F.2d at 238; *Lykes Bros. Steamship Co. v. United States*, 459 F.2d 1393, 1399-1403 (Ct. Cl. 1972); *Aero Spacelines, Inc. v. United States*, 530 F.2d 324, 331-32 (Ct. Cl. 1976).

No case, however, recognizes a legal presumption of patent infringement. Rather, it is long-established that "[i]nfringement must ... be shown by satisfactory proof; it cannot be presumed." *R.R. Co. v. Mellon*, 104 U.S. 112, 119 (1881) (emphasis added).

Here, the panel implicitly created a presumption of infringement in a declaratory judgment action between a licensee and a patent licensor by placing the

burden on a licensee to prove a negative (the absence of infringement).

This Court's precedents hold that the patentee always bears the burden of proof on infringement. *E.g.*, *Under Sea Indus., Inc. v. Dacor Corp.*, 833 F.2d 1551, 1557 (Fed. Cir. 1987). That burden does not shift merely because the action is initiated pursuant to the Declaratory Judgment Act. *E.g.*, *Vivid Techs., Inc. v. Am. Sci. & Eng'g, Inc.*, 200 F.3d 795, 802, 806 (Fed. Cir. 1999). Indeed, this Court held in *Vivid* that in a declaratory judgment action "the parties bore the same evidentiary burdens whether or not the counterclaim was permitted." *Id.* at 802; *see also Advance Transformer Co. v. Levinson*, 837 F.2d 1081, 1084 (Fed. Cir. 1988).

The panel dismissed these fundamental principles, based on the *MedImmune* decision. Slip Op. at 9-10. In doing so, the panel's decision created new law, asserting that it arose "as a consequence of the Supreme Court's decision in *MedImmune, Inc. v. Genentech, Inc.*, 549 U.S. 118 (2007)." Slip Op. at 7. Nothing in *MedImmune* suggests a departure from this settled law.

MedImmune merely holds that a licensee is not required to breach a license agreement and subject itself to treble damages before seeking a declaratory judgment "that the underlying patent is invalid, unenforceable, or not infringed." 549 U.S. at 137 (emphasis added). Nowhere does *MedImmune* shift the ultimate burden of proof on the underlying issues. In fact, the Supreme Court made clear

that “Petitioner is not repudiating or impugning the contract while continuing to reap its benefits. Rather, it is asserting that the contract, properly interpreted, does not prevent it from challenging the patents, and does not require the payment of royalties because the patents do not cover its products and are invalid.” *Id.* at 135 (emphasis added).

Nothing in the Supreme Court’s rationale in *MedImmune* suggests placing a presumption of infringement on Medtronic in this context. The license agreement between Medtronic and Mirowski Family Ventures (“MFV”) does not specifically identify the accused products that are at issue in this suit because neither those products nor the asserted claims existed at the time the agreement was made, and in fact did not exist until more than a decade later. *See* A8000-8039. Instead, in 2007, MFV specifically accused the products of infringement and demanded royalties under the agreement. A8052-53. MFV, therefore, was not “seek[ing] nothing more than to be discharged from the suit,” (Slip Op. at 11), but was instead demanding significant royalties on new products that allegedly infringed newly-granted patent claims. MFV, rather than Medtronic, is the party seeking to change the status quo.

The panel decision profoundly alters the normal paradigm of a patent declaratory judgment action, and creates—for the first time—a presumption of infringement.

BACKGROUND

The underlying dispute relates to MFV's demand for royalties on products that were developed and commercially released years after the parties entered into a license agreement. *See* A8000-39. That 1991 agreement included a license to Medtronic of numerous patents owned by MFV, including the predecessor patent to the patents-in-suit, U.S. Patent No. 4,928,688. A8002, A8032. MFV, however, has not asserted any infringement allegations with respect to the claims of the '688 patent. Instead, the two patents MFV asserted did not issue until 2003 and 2007, and thus did not exist at the time of the agreement. A301, A401, A8052-53.

The products that MFV accused of infringing the patents-in-suit also did not exist in 1991. Under the license agreement, MFV was required to accuse Medtronic of infringement if it believed any new Medtronic device on the market infringed any of the licensed patents. A8005. Medtronic would then have the option of either paying royalties on the new devices, or initiating a declaratory judgment action to challenge the alleged infringement and validity of the MFV patents. *Id.* Nothing in that agreement, however, provided that Medtronic would take on the unique burden of proving why its products did not infringe the specific claims asserted by MFV.

In letters sent on October 3, 2007, and November 20, 2007, MFV accused seven Medtronic products of infringing 29 claims of the patents-in-suit. A8052-53.

Medtronic then filed this declaratory judgment action, contesting the validity of the patents-in-suit as well as MFV's allegations of infringement.

The district court entered judgment in favor of Medtronic because MFV failed to meet its burden of proof on infringement. A116-26. The panel reversed and found, for the first time, that a licensor has no burden to prove its out-of-court infringement allegations that gave rise to the underlying case or controversy.

ARGUMENT

I. The Panel Opinion Directly Conflicts with Precedents Holding the Patentee Bears the Burden of Proof on Infringement Even Where a Declaratory Judgment Defendant Does Not Assert a Counterclaim.

“The burden always is on the patentee to show infringement.” *Under Sea*, 833 F.2d at 1557. The burden to prove infringement remains on the patentee in a declaratory judgment action. *See, e.g., Centricut, LLC v. Esab Group, Inc.*, 390 F.3d 1361, 1363, 1367 (Fed. Cir. 2004); *L & W, Inc. v. Shertech, Inc.*, 471 F.3d 1311, 1314, 1318 (Fed. Cir. 2006). Even the panel recognized that “mere role reversal in a declaratory judgment action does not shift the burden.” Slip. Op. at 9.

This Court has also held that the lack of a counterclaim does not shift the burden of proof to a declaratory judgment plaintiff. *Vivid*, 200 F.3d at 800-02. In *Vivid*, the plaintiff filed a declaratory judgment action seeking a declaration of non-infringement, and the defendant/patentee was not allowed to file a counterclaim for infringement. 200 F.3d at 800-01. This Court stated that “the parties bore the same

evidentiary burdens whether or not the counterclaim was permitted.” *Id.* at 802 (emphasis added) (citing 12 James Wm. Moore et al., *Moore’s Federal Practice* § 57.62[2][d] (3d ed. 1997)); *see also id.* at 806 (“patentee bears the burden of proving infringement”). Similarly, in *Advance Transformer*, the patentee withdrew his counterclaim of infringement prior to trial but continued to make statements to indicate an actual controversy remained between the parties regarding the issue of infringement. 837 F.2d at 1084. This Court held that an actual controversy still existed and concluded that the patentee/defendant did not meet his burden of proving infringement. *Id.*

II. Nothing in *MedImmune* Alters the Traditional Burden of Proof.

The panel dismissed the express holding in *Vivid* merely because it predates *MedImmune*. Slip Op. at 9-10. Nothing in *MedImmune*, however, supports departing from well-established precedent and shifting the burden of proof on infringement away from the patentee. *MedImmune* merely holds that a licensee is not required to breach a license agreement and subject itself to treble damages before seeking a declaratory judgment “that the underlying patent is invalid, unenforceable or not infringed.” 549 U.S. at 137 (emphasis added).

In *MedImmune*, like the instant case, the licensor initiated the dispute by asserting that the licensee’s product infringed a patent under the parties’ license agreement. 549 U.S. at 121-22. The licensee then filed a declaratory judgment

action seeking a determination that the accused product did not infringe the asserted patent. *Id.* at 122-23. In finding that the case presented an actual case or controversy, the Supreme Court stated that when bringing such a declaratory judgment action, the licensee “is not repudiating or impugning the contract while continuing to reap its benefits. Rather, it is asserting that the contract, properly interpreted, does not prevent it from challenging the patents, and does not require the payment of royalties because the patents do not cover its products and are invalid.” 549 U.S. at 135 (emphasis added).

The Supreme Court, therefore, recognized that even in the context of a license agreement, legitimate disputes can arise as to whether a particular product practices a licensed patent, and is therefore subject to a license agreement. This is particularly true where the license does not require “royalties on all products under the sun.” 549 U.S. at 125 n. 6. Of critical significance, the Supreme Court did not hold, or even mention, that in such a context the burden of proof shifted to the licensee to prove non-infringement.

Thus, the Supreme Court in *MedImmune* did not find or create a presumption of infringement in a declaratory judgment action between a licensee and patent licensor. Nothing in *MedImmune* alters or reverses the long-established principle that “[i]nfringement must ... be shown by satisfactory proof; it cannot be presumed.” *R.R. Co.*, 104 U.S. at 119 (emphasis added).

III. *Reliance* Does Not Support the Panel’s Decision Because There Is No Presumption of Infringement.

The panel’s citation of the Eighth Circuit’s decision in *Reliance* does not support the panel’s holding. *Reliance* merely stands for the proposition that the burden of proof can only shift to the party that does not assert the affirmative of the issue if a legal presumption exists.

In *Reliance*, an insurance company brought a declaratory judgment action to determine whether an insured’s death was intentional/suicidal or accidental. 112 F.2d at 236. The Eighth Circuit held that the trial court committed no error in placing the burden of proof upon the plaintiff insurer. *Id.* at 237-38.

In reaching its conclusion, the Court acknowledged that “[i]t is a fundamental rule that the burden of proof in its primary sense rests upon the party who, as determined by the pleadings, asserts the affirmative of an issue.” *Id.* at 238. There, however, the Court recognized that the insured benefitted from a legal presumption against suicide in cases of unexplained death, and thus due to this presumption, if no evidence were presented, the insurer would lose. *See id.*

Thus, it was the legal presumption—not the insured’s lack of a counterclaim—that dictated which party would bear the burden of proof.

This Court's predecessor Court of Claims subsequently explained these principles in *Lykes*. There, the Court refused to place the burden of persuasion¹ regarding the issue of excessive profits on the plaintiff taxpayer simply because it was the plaintiff in an action against the government seeking a redetermination of excessive profits. *See Lykes*, 459 F.2d at 1401-03.

The Court recognized that if the burden of persuasion were placed on the taxpayer plaintiff to prove it realized no excessive profits, it would be equivalent to giving a presumption of validity to the determination of excessive profits, even though no such presumption exists. *See id.* at 1399-1400, 1403. This is the case because without any evidence on an issue, the issue cannot be considered affirmatively established unless a legal presumption exists. *See id.* at 1402-03; *see also Fireman's Fund Ins. Co. v. Videfreeze Corp.*, 540 F.2d 1171, 1176 (3d Cir. 1976) ("which party stands to lose in default of evidence" "actually depends upon which party asserts the affirmative of the issues"); *Am. Eagle Ins. Co. v. Thompson*, 85 F.3d 327, 331 (8th Cir. 1996) (placing burden of proof on declaratory judgment defendant because he "asserted the affirmative of the question asked of the jury and...would lose in the absence of any evidence on the

¹ "Historically, the term ['burden of proof'] has encompassed two separate burdens: the 'burden of persuasion' (specifying which party loses if the evidence is balanced), as well as the 'burden of production' (specifying which party must come forward with evidence at various stages in the litigation)." *Microsoft Corp. v. i4i Ltd. P'ship*, 131 S.Ct. 2238, 2245 n.4 (2011).

issue”); *see also* George E. Dix et al., 2 *McCormick on Evidence* § 344 (Kenneth S. Broun ed., 6th ed. 2006) (“Many writers came to the view that the better rule for all presumptions would provide that anything worthy of the name ‘presumption’ has the effect of fixing the burden of persuasion on the party contesting the existence of the presumed fact.”).

The *Lykes* court also recognized that the burden of proof does not always follow the burden of pleading. 459 F.2d at 1401. It analogized the situation in its case to a declaratory judgment action where the defendant rightfully bears the burden of proof on the principal issue:

[T]he peculiar nature of the suit for a declaration of non-liability may shift that burden to the defendant, the party who originally made the charge or claim, such as patent infringement, which is the basis of the action for a declaration of non-liability.

Id. at 1402 (quoting Borchard, *Declaratory Judgments* 404-05 (2d ed. 1941)). The Court quoted the concurring opinion in *Reliance*:

[W]hen an actual controversy is presented to a court for adjudication through the medium of a suit for a declaratory judgment, the burden of proving, by a fair preponderance of the evidence, the existence of the fact or facts upon which the right and liabilities of the parties depend is upon him who has the affirmative of the issue which forms the basis of the controversy, without regard to whether he is plaintiff or defendant in the suit.

Lykes, 459 F.2d at 1402 (quoting *Reliance*, 112 F.2d at 240-41 (J. Sanborn concurring)); *see also* *Aero Spacelines*, 530 F.2d at 331.

In the present action, there is no presumption of infringement that would lead to shifting the burden of proof to the declaratory judgment plaintiff. *See R.R. Co.*, 104 U.S. at 119. Nor, as discussed above, does *MedImmune* create such a presumption in this context.

The license agreement between Medtronic and MFV also does not create a presumption of infringement as to the accused products. As discussed above, the accused products did not exist at the time the parties entered into the license agreement. As provided for in the license agreement, MFV asserted claims of infringement against these new products in two letters that demanded significant royalty payments. Medtronic is seeking declaratory relief from these unilateral assertions of MFV.

No legal presumption should, or could, attach to MFV's unilateral assertion that would justify shifting the burden of proof on the issue of infringement from the party who would normally bear it. Nothing in the license agreement between the parties expressly provided or in any way contemplated that Medtronic would bear any burden of proof relating to infringement in such a declaratory judgment action over products not yet in existence.

IV. The Panel's Decision Has Dramatic and Far-Reaching Impact.

The panel's decision, which reallocates the burden of proof in declaratory judgment actions that involve licensees and licensors, profoundly changes the legal

landscape and will have a chilling effect on settlement and license agreements.

Settlement and license agreements commonly provide for a license applicable to infringing products without specifically identifying every product (such as future products that do not even exist at the time the license is negotiated) that would or would not be an “infringing product.” *See MedImmune*, 549 U.S. at 121, 125 n.6. If any licensee will now be subject to a presumption that any product it makes or develops in the future is presumed infringing merely because a license agreement exists, a large disincentive has been created for what are currently commonplace agreements.

Furthermore, directing the declaratory judgment plaintiff to prove non-infringement creates insurmountable problems both for declaratory judgment parties and trial courts. For example, under the panel’s decision, the accused infringer would not only have to guess as to what functions or features of an accused product purportedly literally infringe the asserted patent, the accused infringer would have to guess as to the entire theory of literal infringement.

This issue is substantially compounded when it comes to the doctrine of equivalents, where the accused infringer would have to try to identify and disprove every conceivable doctrine of equivalents argument the patentee could theoretically advance. Here, the panel failed to even address the impact of its decision on the burden of proof with respect to the doctrine of equivalents. After

finding that the district court's conclusion that MFV failed to prove literal infringement "can not stand," the panel then held that "[b]ecause we reverse on this basis we need not reach the district court's conclusion regarding [MFV's expert's] opinions on infringement by equivalents." Slip Op. at 13. The panel's decision, therefore, leaves no guidance to the lower courts as to how to conduct discovery or a trial on the issue of the doctrine of equivalents.

The problems with this approach are highlighted by the facts in this case. Here, MFV ultimately accused nine separate Medtronic products of infringing two patents. A109. Those two patents contain well over 300 claims. A301-10; A401-31. Under the panel's decision, Medtronic would have been arguably required to disprove infringement, both literally and under the doctrine of equivalents, of over 300 claims.² Such a result, however, is at odds with the underlying facts. Here, it was MFV, not Medtronic, that was required to identify the specific claims to be litigated, and MFV was allowed to – and did – change those asserted claims during the litigation. A3009-11. To find that MFV had no burden when its own assertions of specific patent claims formed the basis of the underlying dispute requires a willing suspension of all applicable authority.

² In any other licensee-licensor situation, the result of the panel's decision would require a licensee to disprove infringement of every claim in every asserted patent. Here, the parties' agreements limited MFV to asserting only 30 claims. A8044.

The panel's decision leaves many other questions unanswered. For example, would a conclusion that non-infringement was not proven be equivalent to a conclusion of infringement? If a license agreement were later terminated, would a new trial on infringement need to be held with the patentee this time having the burden of proof? What protection would a licensee have against a patent-licensor accusing all of its products of infringement and demanding royalties without any need to present support for its' infringement allegations?

In the end, the panel's ruling will encourage licensors to simply make out-of-court demands for massive amounts of royalties based on general assertions that the licensee's products infringe any of the licensed patents, knowing that the licensor has no requirement to actually prove those infringement allegations. Nothing in *MedImmune* suggests such a drastic departure from the axiomatic rule that the patentee always bears the burden of proving its infringement allegations.

CONCLUSION

For the foregoing reasons, Medtronic requests that the Court grant rehearing or rehearing *en banc*.

Dated: October 18, 2012

By: 

Martin R. Lueck, Esq.

ATTORNEY FOR PETITIONER
MEDTRONIC, INC.

ADDENDUM

**United States Court of Appeals
for the Federal Circuit**

MEDTRONIC INC.,
Plaintiff-Cross Appellant,

v.

**BOSTON SCIENTIFIC CORPORATION
AND GUIDANT CORPORATION,**
Defendants,

AND

MIROWSKI FAMILY VENTURES, LLC,
Defendant-Appellant.

2011-1313, -1372

Appeals from the United States District Court for the District of Delaware in No. 07-CV-0823, Judge Sue L. Robinson.

Decided: September 18, 2012

MARTIN R. LUECK, Robins, Kaplan, Miller & Ciresi L.L.P., of Minneapolis, Minnesota, argued for plaintiff-cross appellant. With him on the brief were JAN M. CONLIN and STACIE E. OBERTS.

ARTHUR I. NEUSTADT, Oblon, Spivak, McClelland, Maier & Neustadt, LLP, of Alexandria, Virginia, argued for defendant-appellant. With him on the brief were THOMAS J. FISHER and JOHN F. PRESPER.

Before LOURIE, LINN, and PROST, *Circuit Judges*.

LINN, *Circuit Judge*.

Medtronic, Inc. (“Medtronic”) filed a complaint in the United States District Court for the District of Delaware seeking declaratory judgment of noninfringement and invalidity of Mirowski Family Ventures, LLC’s (“MFV”) U.S. Reissue Patents No. RE38,119 (“RE’119 Patent”) and No. RE39,897 (“RE’897 Patent”). The district court entered judgment of noninfringement in favor of Medtronic and judgment of validity and enforceability in favor of MFV. *Medtronic, Inc. v. Boston Scientific Corp.*, No. 07-CV-0823 (D. Del. Mar. 30, 2011). MFV appeals the district court’s judgment of noninfringement and Medtronic cross appeals the district court’s claim construction on which its judgment of validity is based.¹ Because the district court relied on a legally incorrect allocation of the burden of proof to find noninfringement in the limited circumstances of this case and incorrectly construed the claim terms in question, this court vacates and remands.

I. BACKGROUND

Between 1969 and 1980, Dr. Morton Mower (“Mower”) worked with Dr. Mieczyslaw Mirowski to develop the first implantable cardioverter defibrillator (“ICD”). An ICD is a device that is implanted into a patient’s chest to monitor

¹ Medtronic has not appealed the district court’s enforceability ruling and that issue is therefore not considered in this appeal.

the patient's heartbeat. When the ICD detects a very rapid heartbeat that could cause cardiac arrest, it shocks the heart causing all muscle fibers to contract and re-synchronize with the sinus node. Thus, the ICD is intended to prevent sudden death from heart attack, but is not designed to improve the general efficacy of the heart. The ICD is therefore not effective for treating heart conditions like congestive heart failure, where the underlying problem is the heart's decreasing ability to pump enough blood.

Between the 1960's and 1980's, Mower also analyzed EKG readings from congestive heart failure patients. Mower realized that slow conduction from one side of the heart to the other might be the cause of the incoordinate contractions that play a role in heart failure. Based on this observation, Mower developed what he called a biventricular pacer, a device that ultimately became known as a cardiac resynchronization therapy ("CRT") device. Mower's CRT device increases the heart's efficacy by causing both the patient's left and right ventricles to contract simultaneously as the heart beats. Mower ultimately patented the CRT device in what are now the RE'119 and RE'897 Patents, both assigned to MFV. MFV exclusively licenses both patents to Guidant Corp.

Medtronic is a leading manufacturer of medical devices and equipment. In 1991, Medtronic entered into a sublicense agreement covering the RE'119 Patent with Eli Lilly & Co., Guidant's predecessor-in-interest of the patents-in-suit. That agreement allowed Medtronic to challenge the RE'119 Patent's validity, enforceability, and scope via a declaratory judgment action. In 2003, as required by the sublicense, Medtronic began paying royalties into escrow while challenging the validity of the RE'119 Patent. Ultimately the parties entered into a Litigation Tolling Agreement ("LTA") that tolled litigation and obligated MFV to inform Medtronic of which Med-

tronic products MFV deemed were covered by the RE'119 Patent, or subsequent reissue patents claiming priority from the RE'119 Patent (here, the RE'897 Patent), and subject to royalty payments. If Medtronic disagreed, the LTA gave Medtronic the right to retain its license and obligated Medtronic to seek a declaratory judgment of noninfringement in the United States District Court for the District of Delaware. In October and November of 2007, MFV identified several Medtronic products that MFV thought practiced its patents. Pursuant to the LTA, on December 17, 2007, Medtronic filed the complaint giving rise to this declaratory judgment action. Because Medtronic remained MFV's licensee, MFV could not counterclaim for infringement of either patent.

Throughout this litigation the parties have disagreed over whether MFV, the patentee, bore the burden of proving infringement, or whether Medtronic, the declaratory judgment plaintiff, bore the burden of proving noninfringement. During discovery, MFV propounded an interrogatory requesting Medtronic to state the basis for its allegation in paragraph twenty-four of its complaint that "Medtronic's Accused Devices do not infringe any valid claim of the '119 Reissue Patent or the '897 Reissue Patent." Complaint at 6, *Medtronic, Inc. v. Boston Scientific Corp.*, No. 07-CV-0823 (D. Del. Mar. 30, 2011), ECF No. 1. Medtronic objected to MFV's interrogatory, maintaining that the burden to prove infringement rested on MFV and that MFV had failed to provide its infringement contentions. Medtronic ultimately responded to the interrogatory with reasons why it felt that its products do not infringe MFV's patents. On the date expert reports were due, Medtronic served the report of its expert, Dr. Charles Love ("Love"). MFV subsequently served the report of its expert, Dr. Ronald Berger ("Berger"). Consistent with MFV's contention that Medtronic bore the burden to prove noninfringement as it alleged in its complaint, Berger's report was largely responsive to

Love's report, and Berger admitted that he did not expressly map the products in question to every limitation of the relevant claims. *Medtronic, Inc. v. Boston Scientific Corp.*, No. 07-CV-0823, slip op. at 22-23 (D. Del. Mar. 30, 2011) ("*Opinion*").

The district court held a bench trial on January 25-28, 2010, and March 13, 2010. The court relied on *Under Sea Industries, Inc. v. Dacor Corp.*, 833 F.2d 1551, 1557 (Fed. Cir. 1987), which states that "[t]he burden always is on the patentee to show infringement," and thus held that "[a]s the parties asserting infringement, defendants bear the burden of proof by a preponderance of the evidence." *Opinion* at 17. "Having determined that defendants, as patentees, have the burden to prove infringement," *id.* at 20, the court found that Berger's testimony lacked sufficient foundation because of his failure to consider "each limitation of each asserted claim in comparison to each accused product before rendering his infringement opinions," and that defendants "failed to prove literal infringement by a preponderance of the evidence," *id.* at 24. The court also found Berger's report and testimony conclusory and insufficient to show that the products infringe the patents under the doctrine of equivalents. *Id.* at 25-26.

Finally, the district court, in conducting its claim construction, relied on portions of the specification that describe the invention in the context of treating congestive heart failure to construe the preamble terms "improving the hemodynamic efficiency of a heart," RE'119 Patent col. 10 ll. 1-2, 25-26, and "bi-ventricular pacemaker," RE'119 Patent col. 11 l. 1, col. 12 l. 1, as limited to the treatment of congestive heart failure. *Opinion* at 12-14; *see, e.g.*, RE'119 Patent col. 1 ll. 18-22 (stating in the specification that "[t]his invention pertains to . . . a method for increasing the cardiac output of a patient suffering from congestive heart failure by stimulating the

heart of the patient at multiple sites simultaneously”), col. 3 ll. 13-15 (stating in the specification that “an objective of the present invention is to provide a cardiac pacer for increasing hemodynamic efficiency of a heart experiencing a conduction deficiency.”).

MFV appeals the district court’s grant of declaratory judgment of no literal infringement and no infringement under the doctrine of equivalents. Medtronic cross appeals the district court’s claim construction ruling. This court has jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).

II. DISCUSSION

A. Standard of Review

Claim construction is a question of law that this court reviews de novo. *Cybor Corp. v. FAS Techs.*, 138 F.3d 1448, 1451 (Fed. Cir. 1998) (en banc). This court also reviews a district court’s other legal conclusions, such as who bears the burden of proof, de novo. *Madey v. Duke Univ.*, 307 F.3d 1351, 1358 (Fed. Cir. 2002).

B. Burden of Proof

MFV argues that because Medtronic is the declaratory judgment plaintiff—the party seeking court action—Medtronic bore the burden of proving noninfringement, a burden it failed to carry. MFV further explains that because of the parties’ licensing agreement, it could not have filed a counterclaim for infringement and the court erred by viewing MFV as a party “asserting infringement.” *Opinion* at 17. MFV points out that all of the cases the district court relied on to conclude that MFV bore the burden to prove infringement are conventional claims for patent infringement by the patentee as contrasted with declaratory judgment actions by licensees. MFV also points out that the parties’ agreement requires Medtronic to initiate litigation by filing a declaratory

judgment action, as it has done in this case, making Medtronic the party seeking relief from the court. Thus, according to MFV, because Medtronic filed a complaint seeking a judgment that its products do not infringe MFV's patents, Medtronic should have to prove that at least one limitation of each claim of MFV's patents is not met by Medtronic's products.

Medtronic counters that, as the district court held, the burden of proving patent infringement always lies with the patentee; that burden never shifts to the accused infringer. *Opinion* at 17. Medtronic cites *Under Sea Industries*, 833 F.2d at 1557 ("The burden always is on the patentee to show infringement."), *Technology Licensing Corp. v. Videotek, Inc.*, 545 F.3d 1316, 1327 (Fed. Cir. 2008) (burden never shifts to an accused infringer), and *Laitram Corp. v. Rexnord, Inc.*, 939 F.2d 1533, 1535 (Fed. Cir. 1991) (patentee must demonstrate every element of the claim), as support for its position. Medtronic also finds the District of Maryland's reasoning persuasive in *MedImmune, Inc. v. Centocor, Inc.*, 271 F. Supp. 2d 762 (D. Md. 2003), where, on similar facts, the court placed the burden on the patentee. Finally, Medtronic argues that because MFV complied with the requirement of the LTA to first notify Medtronic of the products accused to infringe before Medtronic filed the declaratory judgment action, MFV was in fact the party to "assert infringement" notwithstanding that it did not and could not file an infringement counterclaim.

The question before us arises as a consequence of the Supreme Court's decision in *MedImmune, Inc. v. Genentech, Inc.*, 549 U.S. 118 (2007). In *MedImmune* the Court found declaratory judgment jurisdiction notwithstanding the fact that the declaratory judgment plaintiff licensee continued to make royalty payments pursuant to a license. The Court reasoned that a licensee should not be forced to cease royalty payments and risk infringement

liability before the licensee can challenge the extent of coverage of the license. *MedImmune*, 549 U.S. at 134. Thus, *MedImmune* provided licensees with a shield from the economic consequences of challenging their licensors' patents while enabling those licensees to file declaratory judgment suits to clarify the rights and obligations of the parties under their license agreements. This case requires us to determine the proper allocation of the burden of persuasion in the post-*MedImmune* world, under circumstances in which a declaratory judgment plaintiff licensee seeks a judicial decree absolving it of its responsibilities under its license while at the same time the declaratory judgment defendant is foreclosed from counterclaiming for infringement by the continued existence of that license.

Generally, the party seeking relief bears the burden of proving the allegations in his complaint. See *Schaffer ex rel. Schaffer v. Weast*, 546 U.S. 49, 56-57 (2005). "Perhaps the broadest and most accepted idea is that the person who seeks court action should justify the request . . ." *Schaffer*, 546 U.S. at 56 (quoting C. Mueller & L. Kirkpatrick, *Evidence* § 3.1, p. 104 (3d ed. 2003)). "The burdens of pleading and proof with regard to most facts have been and should be assigned to the plaintiff who generally seeks to change the present state of affairs and who therefore naturally should be expected to bear the risk of failure of proof or persuasion." *Id.* (quoting 2 J. Strong, *McCormick on Evidence* § 337, p. 412 (5th ed. 1999)). In *Schaffer*, a school district denied a student educational services under the Individuals with Disabilities Education Act. *Id.* at 54-55. The student filed suit against the school district and the Court considered which party bore the burden of proving the student was entitled to the services. After finding no guidance in the statute the Court applied "the ordinary default rule that plaintiffs bear the risk of failing to prove their claims," *id.* at 56-57,

and placed the burden on the student, “where it usually falls, upon the party seeking relief,” *id.* at 58.

It is, of course, well settled that a patentee who files a complaint or counterclaim alleging patent infringement bears the burden of proving that infringement. *See Under Sea Indus.*, 833 F.2d at 1557; *In re Tech. Licensing Corp.*, 423 F.3d 1286, 1288-89 (Fed. Cir. 2005); *see also Tech. Licensing Corp. v. Videotek, Inc.*, 545 F.3d 1316, 1327 (Fed. Cir. 2007); *Laitram Corp. v. Rexnord, Inc.*, 939 F.2d 1533, 1535 (Fed. Cir. 1991). In the absence of a license, this court has recognized “that when the same patent is at issue in an action for declaration of non-infringement, a counterclaim for patent infringement is compulsory and if not made is deemed waived.” *Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc.*, 200 F.3d 795, 802 (Fed. Cir. 1999).

The substantive burden of proof normally does not shift simply because the party seeking relief is a counterclaiming defendant in a declaratory judgment action. *See In re Tech. Licensing Corp.*, 423 F.3d at 1288-89 (citing *In re Lockwood*, 50 F.3d 966, 976 (Fed. Cir. 1995) and recognizing that a declaratory judgment action of invalidity with an infringement counterclaim is nothing more than an inverted infringement suit); *Ranbaxy Pharms. Inc. v. Apotex, Inc.*, 350 F.3d 1235, 1237, 39-40 (Fed. Cir. 2003) (requiring patentee seeking preliminary injunction on infringement counterclaim to show *inter alia* a likelihood of proving infringement). In *Vivid Technologies*, this court explained that “the parties bore the same evidentiary burdens whether or not the counterclaim was permitted,” but did not further discuss what those burdens were. 200 F.3d at 802. Moreover, that statement was made before the Supreme Court’s *MedImmune* decision and was based on the general proposition that mere role reversal in a declaratory judgment action does not shift the burden. *Id.* Specifically, *Vivid Technologies* quoted *Moore’s Federal Practice* that “in patent cases ‘courts have

generally recognized that any role reversal occasioned by declaratory relief should not shift the burden of proof from the manner in which it would be assigned in a coercive infringement suit.” *Id.* (quoting 12 James Wm. Moore et al., *Moore’s Federal Practice* 57.62[2][d] (3d ed. 1997)). But *Moore’s Federal Practice* did not consider allocating the burden of proof post-*MedImmune*, when “a coercive infringement suit” was not possible and therefore did not address Medtronic’s simple role reversal argument at issue here.

These cases only stand for the rote proposition that when there is a direct claim for infringement, in a complaint or by way of counterclaim, the patentee cannot prevail without proving all the elements of infringement under 35 U.S.C. § 271. And in the customary declaratory judgment case, like *Vivid Technologies*, the declaratory judgment defendant must assert a counterclaim for infringement to avoid risking the loss of that claim forever. *See id.* But this is not such a case. In this case, as sanctioned by *MedImmune*, the continued existence of the license precludes the very infringement counterclaim that normally would impose the burden of proving infringement on the patentee. Here, Medtronic is shielded from any liability for infringement by its license. And MFV has not asserted a claim of infringement, nor could it because of the license. Thus, while Medtronic’s suit for declaratory judgment undoubtedly rests upon the infringement provisions laid out in § 271, the relief it seeks relates directly to its obligations under the license.

The contract at issue here required MFV to identify products it believed were covered by the contract. After MFV identified those products, Medtronic was required to either pay royalties on them, or sue for declaratory judgment that the products were not covered. Medtronic is unquestionably the party now requesting relief from the court: it already has a license; it cannot be sued for in-

fringement; it is paying money into escrow; and it wants to stop. In contrast, regarding the patents at issue here, MFV seeks nothing more than to be discharged from the suit and be permitted to continue the quiet enjoyment of its contract.² In other words, it is Medtronic and not MFV that is asking the court to disturb the status quo ante and to relieve it from a royalty obligation it believes it does not bear. Consistent with the above, for the court to disturb the status quo ante, Medtronic must present evidence showing that it is entitled to such relief. If neither party introduced any evidence regarding infringement or noninfringement there is no principled reason why Medtronic should receive the declaration of noninfringement it seeks.

This analysis is fully consistent with other areas of the law. In insurance cases, courts generally place the burden on the party seeking recovery under a policy. This is true even when the insured is the declaratory judgment defendant. See *Am. Eagle Ins. Co. v. Thompson*, 85 F.3d 327, 331 (8th Cir. 1996) (“Stripped of its procedural posture, this action is, at base, a claim by Thompson [the insured who ultimately bore the burden] that he is covered under an insurance policy and a denial by the insurer [declaratory judgment plaintiff] that coverage properly exists.”). But the burden can shift to the declaratory judgment plaintiff where the insured is not seeking affirmative relief. See *Reliance Life Ins. Co. v. Burgess*, 112 F.2d 234, 237 (8th Cir. 1940) (holding that when the declaratory judgment defendant insureds “asked no affirmative relief [and] prayed only to be dis-

² MFV initially counterclaimed for declaratory judgment of its right to recover money paid into escrow under the 2003 escrow agreement regarding U.S. Patent No. 4,407,288. This counterclaim was dismissed without prejudice pursuant to joint stipulation by the parties and is not at issue in this appeal.

charged with their costs,” the burden fell on the declaratory judgment plaintiff insurance company). The Third Circuit cited *Burgess* as “[t]he leading case which expounded the[] guiding principles” for allocating the burden of proof in a declaratory judgment action. *Fireman’s Fund Ins. Co. v. Videfreeze Corp.*, 540 F.2d 1171, 1175 (3d Cir. 1974) (also noting that the burden often falls on the insurer in personal disability insurance cases where the issue is whether the insured is able to return to work and the insurer may cease making payments).

As noted, neither party here seeks money damages or an injunction based on patent infringement, which are the sorts of relief generally sought when a party seeks relief for patent infringement. Instead, the one claim for relief sought in this case is the claim Medtronic asserts to be relieved from liability under the license by having a court declare the products in question to be noninfringing. Medtronic is the party seeking this relief and Medtronic must bear the burden of proving it is entitled to such relief. A contrary result would allow licensees to use *MedImmune’s* shield as a sword—haling licensors into court and forcing them to assert and prove what had already been resolved by license. Because the declaratory judgment plaintiff is the only party seeking the aid of the court in the circumstances presented here, that party must bear the burden of persuasion. Therefore, this court holds that in the limited circumstance when an infringement counterclaim by a patentee is foreclosed by the continued existence of a license, a licensee seeking a declaratory judgment of noninfringement and of no consequent liability under the license bears the burden of persuasion.

In view of the above holding, the district court’s finding that Berger’s expert testimony lacked sufficient foundation because his report “fail[ed] to demonstrate that [he] considered each limitation of each asserted claim in

comparison to each accused product before rendering his infringement opinions” was clearly erroneous. *Opinion* at 24. MFV did not bear that burden of proof and its expert was therefore not obliged to do more than rebut Medtronic’s contentions. The district court’s conclusion that “[d]efendants have failed to prove literal infringement by a preponderance of the evidence” can not stand. *Id.* Because we reverse on this basis we need not reach the district court’s conclusion regarding Berger’s opinions on infringement by equivalents. We also need not address MFV’s argument that Medtronic’s interrogatory responses effectively conceded that all unaddressed claim limitations were satisfied. Because Medtronic, and ultimately the district court, did not appreciate the appropriate allocation of the burden of proof and how the burden affected the parties’ conduct during discovery, it is within the district court’s discretion on remand whether to limit Medtronic to its current interrogatory answer, or to allow Medtronic to amend its interrogatory answer to include any additional noninfringement contentions it may wish to assert.

C. Claim Construction

In its cross-appeal, Medtronic contends that the district court based its refusal to find the patents invalid on an erroneous claim construction. Medtronic argues that the district court improperly restricted the asserted claims of the RE’119 patent to treating congestive heart failure based only on the specification’s disclosure of such treatment; nothing in the specification disclaims using the invention to treat other conditions. According to Medtronic, the specification is very broad and provides examples of treating many conditions caused by conduction deficiency—some unrelated to heart failure (e.g., bundle branch blocks). Medtronic argues that the patentee did not expressly narrow or clearly disavow a broader claim scope. Finally, Medtronic notes that claim

171 of the RE'897 Patent specifically recites the limitation of "improv[ing] the pumping ability of the heart suffering from heart failure," while the other, broader claims do not. RE'897 Patent col. 21 ll. 34-35.

MFV argues that the patentee expressly defined his invention for use only in congestive heart failure. MFV also stresses that the inventor described the invention's use for treating congestive heart failure as a way to distinguish this invention from a prior art reference ("Funke"). See RE'119 Patent col. 2 ll. 28-33. Finally, MFV cites *SafeTCare Manufacturing, Inc. v Tele-Made, Inc.*, 497 F.3d 1262 (Fed. Cir. 2007), to argue that it is only trying to understand what the patentee has claimed and disclaimed, not to import limitations from the specification into the claims.

"[T]he words of a claim 'are generally given their ordinary and customary meaning' . . . that the term would have to a person of ordinary skill in the art in question at the time of the invention . . ." *Phillips v. AWH Corp.*, 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc) (citations omitted). That person of ordinary skill in the art is deemed to understand the terms in the context of the entire patent, including the specification, *id.* at 1313, but the claim terms should not be limited to the disclosed embodiments, *id.* at 1323. Rather, claim terms should generally be given their ordinary and customary meaning unless "1) when a patentee sets out a definition and acts as his own lexicographer, or 2) when the patentee disavows the full scope of a claim term either in the specification or during prosecution." *Thorner v. Sony Computer Entm't Am. LLC*, 669 F.3d 1362, 1365 (Fed. Cir. 2012). "To act as its own lexicographer, a patentee must 'clearly set forth a definition of the disputed claim term . . .'" *Id.* (quoting *CCS Fitness, Inc. v. Brunswick Corp.*, 288 F.3d 1359, 1366 (Fed. Cir. 2002)). And "[w]here the specification makes clear that the invention does not include a

particular feature, that feature is deemed to be outside . . . the patent,” even if the terms might otherwise be broad enough to cover that feature. *Id.* at 1366 (internal citation omitted).

Here, the district court did nothing more than append the limitation “for the treatment of congestive heart failure,” onto the ends of the disputed claim terms. *Opinion* at 12-14. This unquestionably added a limitation. This would only have been proper if the patentee specifically defined the terms to include that limitation, or disavowed their otherwise broad scope. While the specification explains the use of the invention to treat congestive heart failure, it also discloses the invention’s value in treating other diseases. *See, e.g.*, RE’119 Patent col. 3 ll. 13-15 (“an objective of the present invention is to . . . [treat] a heart experiencing a conduction deficiency.”). As for the prior art Funke reference, the prosecution history reveals that the patentee distinguished Funke based on the placement of electrodes to stimulate only the ventricles, not based on any express use of the disclosed device to treat any particular condition. The statement in the specification that Funke does not disclose his invention’s “specific use as a method of improving the cardiac output of patients suffering from congestive heart failure,” RE’119 Patent col. 2 ll. 30-32, is a far cry from the clear disavowal needed to limit the claims of the RE’119 Patent. Moreover, inclusion of the express limitation “to improve the pumping ability of the heart suffering from heart failure,” RE’897 Patent col. 21 ll. 33-35, in claim 171 of the RE’897 Patent, a continuation of the RE’119 Patent, suggests that the other claims that do not recite such a limitation should not be so limited. We therefore conclude that the district court erred by restricting the claimed invention to the treatment of congestive heart failure. The district court’s determination of no invalidity predicated on its improper claim construction is vacated. On remand, Medtronic

may press its invalidity contention based upon the correct claim construction.

CONCLUSION

For the foregoing reasons, the judgment of the district court is vacated, and the case is remanded for additional proceedings consistent with this opinion.

VACATED AND REMANDED

COSTS

Each of the parties shall bear its own costs.

CERTIFICATE OF SERVICE

I certify that the original and 18 copies of the foregoing COMBINED PETITION OF MEDTRONIC, INC. FOR PANEL REHEARING AND REHEARING *EN BANC* were filed with the Clerk of the United States Court of Appeals for the Federal Circuit by overnight courier, next day delivery, this 16th day of October, 2012.

I also certify that two copies of the foregoing petition were served by overnight courier, next day delivery, this 16th day of October, 2012, upon counsel of record, below.

Arthur I. Neustadt, Esq.
Thomas J. Fisher, Esq.
John F. Presper, Esq.
**OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, LLP**
1940 Duke Street
Alexandria, VA 22314



Martin R. Lueck